New York State Teachers Retirement System Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

New York State Teachers Retirement System raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,576 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,322 shares during the period. New York State Teachers Retirement System owned 0.17% of Supernus Pharmaceuticals worth $3,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. Stephens Investment Management Group LLC grew its stake in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after acquiring an additional 33,710 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 1.1% during the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after acquiring an additional 7,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 14.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after acquiring an additional 91,354 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 4.5 %

Shares of NASDAQ:SUPN opened at $33.05 on Friday. The company has a market capitalization of $1.83 billion, a PE ratio of 30.89 and a beta of 0.90. The business has a 50 day moving average of $37.48 and a two-hundred day moving average of $35.30. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $57.00 to $36.00 in a report on Wednesday.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.